Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
-
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Anti-agalsidase antibodies
Bioelectrical impedance analysis
Biomarker
Inclusion body myositis
Female
AAV
Middle Aged
Anti-drug antibodies
Data integration
Anti-interleukin-6
Amyotrophy
Myositis
Antibodies
Sphingosine-1-phosphate
Antibody responses
Acute Kidney Injury/epidemiology/etiology
Anti-Mi2
Machine learning
B cell homeostasis
Anti-MDA5 autoantibodies
Amyotrophic lateral sclerosis
Lysosomal storage diseases
Arthritis
Pharmacology
Myopathy
Anti-IgE IgG
Aged
Biomarqueurs
Anémie hémolytique
Active
Immunotherapy
Antisynthetase
Muscle
IBM
Humans
Analyses multidimensionnelles
Biomarkers
Idiopathic inflammatory myopathies
Outcome measures
AAV vector
Autoantibody
AAV antibody
DM
Myocarditis
Autoimmunity
Deep immune profiling
Prognosis
Multidisciplinarity
Assisted communication devices
Adeno-associated vector
Interstitial lung disease
Adeno-associated virus vector
Immune checkpoint inhibitors
Aldosterone
Interferon
Adolescence
Male
Acid-alpha-glucosidase
Inborn errors of metabolism
Aldostérone
Animals
Adult
AAV humoral immunity
Mass cytometry
Adverse drug reactions
Systems biology
Cardio-oncology
Dermatomyositis
Adjudication
Autoimmune diseases
COVID-19
IMNM
Inflammation
Fabry disease
Inflammatory myopathy
Anticorps spécifique des myosites
Auto‐antibodies
Auto-antibodies
Antiphospholipid syndrome
AAV vectors
Case reports
Agalsidase
Polymyositis
Adeno-associated virus
Anti‐mitochondrial antibodies
Gene therapy
Antisynthétase
Anticorps anti-agalsidase
Auto-immunité
Anti-synthetase syndrome
Abnormal movement
Antisynthetase syndrome
Biopsy
Skeletal muscle
Myositis and muscle disease
Cytokines
Cancer
Dependovirus/genetics/immunology
B-lymphocyte
Autoantibodies